Abstract
Because of the presence of cell membrane somatostatin receptors (SSTRs), many neuroendocrine tumors will bind analogs of somatostatin. 90Y-Dodecanetetraacetic acid-Phe1-Tyr3-octreotide (SMT 487) is an SSTR radiopharmaceutical currently under investigation as a therapeutic option for neuroendocrine tumors. Although there are a variety of methods for evaluating response to a given cancer therapy, an important indicator of success is the impact on the clinical status of the patient. The purpose of this work was to develop a semiquantitative method and assess the clinical effectiveness of 90Y-SMT 487 therapy in patients with neuroendocrine tumors. Methods: A scoring system was developed to evaluate clinical response that included the following parameters: weight, health status score (determined by the patient), Karnofsky score, and tumor-related symptoms. Results: We applied this scoring system to 21 patients who had completed 3 cycles of therapy with 90Y-SMT 487. Fourteen of the 21 showed a favorable clinical response, whereas 5 were clinically stable after treatment and 2 showed evidence of clinical progression. There was also a significant reduction in the amount of octreotide being used after completion of 90Y-SMT 487 therapy in the 20 patients who were on this medication. Conclusion: Using this scoring method, 90Y-SMT 487 appears effective in improving the clinical status of patients with 111In-pentetreotide-positive neuroendocrine tumors.
Footnotes
Received Jan. 21, 2003; revision accepted Jun. 13, 2003.
For correspondence or reprints contact: David Bushnell, MD, Diagnostic Imaging and Radioisotope Therapy Service, Iowa City Veterans Administration Hospital, Highway 6 West, Iowa City, IA 52240.
E-mail: david-bushnell{at}uiowa.edu
In this issue
Jump to section
Related Articles
Cited By...
- Management of neuroendocrine tumors
- Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors
- Molecular radiotherapy
- Radiopeptide Imaging and Therapy in the United States
- Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
- 90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide
- Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors
- Treatment of Metastatic Carcinoid Tumors With Radiolabeled Biologic Molecules
- Utility of Radiolabeled Somatostatin Receptor Analogues for Staging/Restaging and Treatment of Somatostatin Receptor-Positive Pediatric Tumors
- Potential Increased Tumor-Dose Delivery with Combined 131I-MIBG and 90Y-DOTATOC Treatment in Neuroendocrine Tumors: A Theoretic Model
- Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues
- Evaluation of [99mTc/EDDA/HYNIC0]Octreotide Derivatives Compared with [111In-DOTA0,Tyr3, Thr8]Octreotide and [111In-DTPA0]Octreotide: Does Tumor or Pancreas Uptake Correlate with the Rate of Internalization?
- Preclinical Evaluation of New and Highly Potent Analogues of Octreotide for Predictive Imaging and Targeted Radiotherapy
- Overview of Results of Peptide Receptor Radionuclide Therapy with 3 Radiolabeled Somatostatin Analogs
- 68Ga-Labeled Peptides in Tumor Imaging
- Combination Radionuclide Therapy Using 177Lu- and 90Y-Labeled Somatostatin Analogs
- Patient-Specific Dosimetry in Predicting Renal Toxicity with 90Y-DOTATOC: Relevance of Kidney Volume and Dose Rate in Finding a Dose-Effect Relationship